Sung Ji Nam
Stock Analyst at Scotiabank
(3.71)
# 742
Out of 5,090 analysts
83
Total ratings
50.72%
Success rate
8.59%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $102.02 | -41.19% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $61.68 | +21.60% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $226.25 | +21.55% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $572.77 | +3.01% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $128.96 | -3.07% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $38.65 | +3.49% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $7.68 | +421.17% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $7.09 | -15.37% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.68 | +138.10% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $2.39 | -16.32% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $101.06 | -27.77% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $14.75 | -18.64% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $394.81 | +13.98% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $32.30 | +91.95% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $44.61 | -1.37% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $18.53 | +88.88% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.80 | +25.00% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.79 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $102.02
Upside: -41.19%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $61.68
Upside: +21.60%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $226.25
Upside: +21.55%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $572.77
Upside: +3.01%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $128.96
Upside: -3.07%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $38.65
Upside: +3.49%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $7.68
Upside: +421.17%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $7.09
Upside: -15.37%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.68
Upside: +138.10%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $2.39
Upside: -16.32%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $101.06
Upside: -27.77%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $14.75
Upside: -18.64%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $394.81
Upside: +13.98%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $32.30
Upside: +91.95%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $44.61
Upside: -1.37%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $18.53
Upside: +88.88%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.80
Upside: +25.00%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $27.79
Upside: -